gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLC10.22416/1382-4376-2022-32-3-7-11gastro-j-653Research ArticleОБЗОРЫREVIEWSСовременные подходы к вакцинации против новой коронавирусной инфекции пациентов с хроническими заболеваниями печени и воспалительными заболеваниями кишечникаModern Approaches to Vaccination of Patients with Chronic Liver Diseases and Inflammatory Bowel Diseases against a Novel Coronavirus Infectionhttps://orcid.org/0000-0002-1395-9566ШептулинА. А.SheptulinA. A.

Шептулин Аркадий Александрович – доктор медицинских наук, профессор кафедры пропедевтики внутренних болезней, гастроэнтерологии и гепатологии Института клинической медицины им. Н.В. Склифософского

119435 Москва, ул. Погодинская, д. 1, стр. 1

Arkadiy A. Sheptulin – Dr. Sci. (Med.), Prof., Department of Internal Diseases Propedeutics, Gastroenterology and Hepatology

119435, Moscow, Pogodinskaya str., 1/1

arkalshep@gmail.comhttps://orcid.org/0000-0002-6815-6015ИвашкинВ. Т.IvashkinV. T.

Ивашкин Владимир Трофимович — доктор медицинских наук, академик РАН, профессор, заведующий кафедрой пропедевтики внутренних болезней, гастроэнтерологии и гепатологии, директор клиники пропедевтики внутренних болезней, гастроэнтерологии и гепатологии им. В.Х. Василенко

119435 Москва, ул. Погодинская, д. 1, стр. 1

Vladimir T. Ivashkin – Dr. Sci. (Med.), RAS Academician, Prof., Departmental Head, Department of Propaedeutics of Internal Diseases, N.V. Chief of Vasilenko Clinic of Internal Disease Propaedeutics, Gastroenterology and Hepatology

119435, Moscow, Pogodinskaya str., 1/1

kont07@yandex.ruФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» (Сеченовский Университет) Министерства здравоохранения Российской ФедерацииSechenov First Moscow State University (Sechenov University)202209082022323711Copyright © Шептулин А.А., Ивашкин В.Т., 20222022Шептулин А.А., Ивашкин В.Т.Sheptulin A.A., Ivashkin V.T.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/653        

        

Цель исследования

Цель исследования: провести анализ данных литературы, посвященных особенностям вакцинации пациентов с хроническими заболеваниями печени (ХЗП) и воспалительными заболеваниями кишечника (ВЗК) против инфекции COVID-19

Основные положения

Основные положения. Показано, что многие больные с ХЗП (циррозом печени, неалкогольной жировой болезнью печени) имеют более высокий риск тяжелого течения новой коронавирусной инфекции, что обусловливает необходимость их вакцинации. Больные ВЗК также подлежат вакцинации, хотя принимаемые ими иммуномодулирующие препараты могут снижать ее эффективность. Кроме того, большое значение имеет правильный выбор времени введения вакцины. Вакцинация больных ХЗП и ВЗК безопасна, и частота побочных эффектов при ее проведении не отличается от таковой в общей популяции.

Заключение

Заключение. Анализ данных литературы показывает, что пациенты с ХЗП и ВЗК подлежат вакцинации против инфекции COVID-19, которая является эффективной и безопасной.

Aim

Aim. To analyze the literature data on the peculiarities of vaccination of patients with chronic liver diseases (CLD) and inflammatory bowel diseases (IBD) against COVID-19 infection.

Key findings

Key findings. It has been shown that many patients with CLD (cirrhosis of the liver, non-alcoholic fatty liver disease) have a higher risk of severe course of a novel coronavirus infection, which necessitates their vaccination. IBD patients are also subject to vaccination, although the immunomodulatory drugs which they take may reduce its effectiveness. In addition, the correct timing of the vaccine administration is of great importance. Vaccination of patients with CLD and IBD is safe, and the frequency of side effects during its implementation does not differ from that in the general population.

Conclusion

Conclusion. Analysis of literature data shows that patients with CLD and IBD are subject to vaccination against COVID-19 infection, which is effective and safe. 

хронические заболевания печенивоспалительные заболевания кишечникановая коронавирусная инфекциявакцинациясhronic liver diseaseinflammatory bowel diseasenovel coronavirus infectionvaccinationReferencesCornberg M., Buti M., Eberhardt C.S., Grossi P.A., Shouvai D. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. J Hepatol. 2021;74(4):944–51. DOI: 10.1016/j.hep.2021.01.032Cornberg M., Buti M., Eberhardt C.S., Grossi P.A., Shouvai D. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. J Hepatol. 2021;74(4):944–51. DOI: 10.1016/j.hep.2021.01.032Ивашкин В.Т., Шептулин А.А., Зольникова О.Ю., Охлобыстин А.В., Полуэктова Е.А., Трухманов А.С. и др. Новая коронавирусная инфекция (COVID-19) и система органов пищеварения. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(3):7-13. DOI: 10.22416/1382-4376-2020-30-3-7Ivashkin V.T., Sheptulin A.A., Zolnikova O.Yu., Okhlobystin A.V., Poluektova E.A., Trukhmanov A.S., et al. New Coronavirus Infection (COVID-19) and Digestive System. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(3):7–13 (In Russ.). DOI: 10.22416/1382-4376-2020-30-3-7Russo F.P., Piano S., Bruno R., Burra P., Puoti M., Masarone M., et al. Italian Association for the Study of the Liver position statement on SARS-COV-2 vaccination. Digestive and Liver Disease. 2021;53:677–81. DOI: 10.1016/j.did.2021.03.013Russo F.P., Piano S., Bruno R., Burra P., Puoti M., Masarone M., et al. Italian Association for the Study of the Liver position statement on SARS-COV-2 vaccination. Digestive and Liver Disease. 2021;53:677–81. DOI: 10.1016/j.did.2021.03.013Sharma A., Patnaik I., Kumar A., Gupta R. COVID-19 vaccines in patients with liver disease. J Clin Exp Hepatol. 2021;11(6):720–6. DOI: 10.1016/j.jceh.2021.06.013Sharma A., Patnaik I., Kumar A., Gupta R. COVID-19 vaccines in patients with liver disease. J Clin Exp Hepatol. 2021;11(6):720–6. DOI: 10.1016/j.jceh.2021.06.013Fix O.K., Blumberg E.A., Chang K.-M., Chu J., Chung R.T., Goacher E.K., et al. AASLD Expert panel consensus statement: vaccines to prevent COVID-19 infection in patients with liver diseases. Hepatology. 2021. DOI: 10.1002/hep.31751Fix O.K., Blumberg E.A., Chang K.-M., Chu J., Chung R.T., Goacher E.K., et al. AASLD Expert panel consensus statement: vaccines to prevent COVID-19 infection in patients with liver diseases. Hepatology. 2021. DOI: 10.1002/hep.31751Peck-Radosavljevic M., Burra P., Ferret M.B., Fracasso P., Ricciardiello L., Seufferlein T., et al. Covid-19 and digestive health: Implications for prevention, care and the use of COVID-19 vaccines in vulnerable patients. UEG Journal. 2021;9:1091–195. DOI: 10.1002/ueg2.12173Peck-Radosavljevic M., Burra P., Ferret M.B., Fracasso P., Ricciardiello L., Seufferlein T., et al. Covid-19 and digestive health: Implications for prevention, care and the use of COVID-19 vaccines in vulnerable patients. UEG Journal. 2021;9:1091–195. DOI: 10.1002/ueg2.12173Wang J., Hou Z., Liu J., Gu Y., Wu Y., Chen Z., et al. Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): a multicenter study. J Hepatol. 2021;75(2):439–41. DOI: 10.1016/j.jhep.2021.04.026Wang J., Hou Z., Liu J., Gu Y., Wu Y., Chen Z., et al. Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): a multicenter study. J Hepatol. 2021;75(2):439–41. DOI: 10.1016/j.jhep.2021.04.026Moon A.M., Webb G.J., Garcia-Juarez I., Kulkarni A.V., Adali G., Wong D.K., et al. SARS-CoV-2 infections among patients with liver disease and liver transplantation who received COVID-19 vaccination. Hepatology Communications. 2021;0(0):1–9.Moon A.M., Webb G.J., Garcia-Juarez I., Kulkarni A.V., Adali G., Wong D.K., et al. SARS-CoV-2 infections among patients with liver disease and liver transplantation who received COVID-19 vaccination. Hepatology Communications. 2021;0(0):1–9.Prentice R.E., Rentsch C., Al-Ani A., Zhang E., Johnson D., Halliday J., et al. SARS-CoV-2 vaccination in patients with inflammatory bowel disease. Gastro Hep. 2021;3(4):212–26. DOI: 10.10002/ygh2.473Prentice R.E., Rentsch C., Al-Ani A., Zhang E., Johnson D., Halliday J., et al. SARS-CoV-2 vaccination in patients with inflammatory bowel disease. Gastro Hep. 2021;3(4):212–26. DOI: 10.10002/ygh2.473Wellens J., Colombel J.-F., Satsangi J.J., Wong S.-Y. SARS-CoV-2 vaccination in IBD: past lessons, current evidence, and future challenges. J Crohn’s Colitis. 2021;15(8):1376–86. DOI: 10.1093/ecco-jcc/jjab046Wellens J., Colombel J.-F., Satsangi J.J., Wong S.-Y. SARS-CoV-2 vaccination in IBD: past lessons, current evidence, and future challenges. J Crohn’s Colitis. 2021;15(8):1376–86. DOI: 10.1093/ecco-jcc/jjab046Maconi G., Bosetti C., De Monti A., Boyapati R.K., Shelton E., Piazza N., et al. Risk of COVID-19 in patients with inflammatory bowel diseases compared to a control population. Dig Liver Dis. 2021;53(3):263–70. DOI: 10.1016/j.dld.2020.12.013Maconi G., Bosetti C., De Monti A., Boyapati R.K., Shelton E., Piazza N., et al. Risk of COVID-19 in patients with inflammatory bowel diseases compared to a control population. Dig Liver Dis. 2021;53(3):263–70. DOI: 10.1016/j.dld.2020.12.013Siegel C.A., Melmed G.Y., McGovern D.P.B., Rai V., Krammer F., Rubin D.T., et al. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut. 2021;70(4):635–40. DOI: 10.1136/gutjnl-2020-324000Siegel C.A., Melmed G.Y., McGovern D.P.B., Rai V., Krammer F., Rubin D.T., et al. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut. 2021;70(4):635–40. DOI: 10.1136/gutjnl-2020-324000Lee Y.J., Kim S.-E., Park Y.E., Chang J.Y., Song H.J., Kim D.H., et al. SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: Expert consensus statements by KASID. Korean J Gastroenterol. 2021;78(2):117–28. DOI: 10.4166/kfg.2021.110Lee Y.J., Kim S.-E., Park Y.E., Chang J.Y., Song H.J., Kim D.H., et al. SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: Expert consensus statements by KASID. Korean J Gastroenterol. 2021;78(2):117–28. DOI: 10.4166/kfg.2021.110Alexander J.L., Moran G.M., Gaya D.R., Raine T., Hart A., Kennedy N.A., et al. SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease Section and IBD Clinical Research Group position statement. Lancet Gastroenterol Hepatol. 2021;6(3):218–24. DOI: 10.1111/apt.16590Alexander J.L., Moran G.M., Gaya D.R., Raine T., Hart A., Kennedy N.A., et al. SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease Section and IBD Clinical Research Group position statement. Lancet Gastroenterol Hepatol. 2021;6(3):218–24. DOI: 10.1111/apt.16590Dalai R.S., McClure E., Marcus J., Winter R.W., Hamilton M.J., Allegretti J.R. COVID-19 vaccination and perceptions among patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2021;19(8):1730–2. DOI: 10.1016/j.cgh.2021.02.004Dalai R.S., McClure E., Marcus J., Winter R.W., Hamilton M.J., Allegretti J.R. COVID-19 vaccination and perceptions among patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2021;19(8):1730–2. DOI: 10.1016/j.cgh.2021.02.004Edelman-Klapper H., Zittan E., Bar-Gill Shitrit A., Rabinowitz B.-G., Goren I., Avni-Biron I., et al. Lower serologic response to COVID-19 mRNA vaccine in patients with inflammatory bowel diseases treated with anti-TNF-alpha. Gastroenterlogy. 2021:S0016-5085(21)03701-X. DOI: 10.1053/j.gastro.2021.10.029Edelman-Klapper H., Zittan E., Bar-Gill Shitrit A., Rabinowitz B.-G., Goren I., Avni-Biron I., et al. Lower serologic response to COVID-19 mRNA vaccine in patients with inflammatory bowel diseases treated with anti-TNF-alpha. Gastroenterlogy. 2021:S0016-5085(21)03701-X. DOI: 10.1053/j.gastro.2021.10.029Kennedy N.A., Lin S., Goodhand J.R., Chanchlani N., Hamilton B., Bewshea C., et al. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut. 2021;70(10):1884–93. DOI: 10.1136/gutjnl-2021-324789Kennedy N.A., Lin S., Goodhand J.R., Chanchlani N., Hamilton B., Bewshea C., et al. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut. 2021;70(10):1884–93. DOI: 10.1136/gutjnl-2021-324789Khan N., Mahmud N. Effectiveness of SARS-CoV-2 vaccination in a veterams affairs cohort of patients with inflammatory bowel disease with diverse exposure to immunosuppressive medications. Gastroenterology. 2021;161(3):827–36. DOI: 10.1053/j.gastro.2021.05.044Khan N., Mahmud N. Effectiveness of SARS-CoV-2 vaccination in a veterams affairs cohort of patients with inflammatory bowel disease with diverse exposure to immunosuppressive medications. Gastroenterology. 2021;161(3):827–36. DOI: 10.1053/j.gastro.2021.05.044Cerna K., Durikova D., Lukas M., Machkova N., Hruba V., Mitrova K., et al. Anti-SARS-CoV-2 vaccination and antibody response in patients with inflammatory bowel disease on immune-modifying therapy; prospective single-tertiary study. Inflamm Bowel Dis. 2021:izab 301. DOI: 10.1093/ibd/izab301Cerna K., Durikova D., Lukas M., Machkova N., Hruba V., Mitrova K., et al. Anti-SARS-CoV-2 vaccination and antibody response in patients with inflammatory bowel disease on immune-modifying therapy; prospective single-tertiary study. Inflamm Bowel Dis. 2021:izab 301. DOI: 10.1093/ibd/izab301Tepasse P.R., Vollenberg R., Nowacki T.M. Vaccination against SARS-CoV-2 in patients with inflammatory bowel diseases: where do we stand? Life (Basel). 2021;11(11):1220. DOI: 10.3390/life11111220Tepasse P.R., Vollenberg R., Nowacki T.M. Vaccination against SARS-CoV-2 in patients with inflammatory bowel diseases: where do we stand? Life (Basel). 2021;11(11):1220. DOI: 10.3390/life11111220Botwin G.J., Li D., Figueiredo J., Cheng S., Braun J., McGovern D.P.B., et al. Adverse events after SARSCoV-2 mRNA vaccination among patients with inflammatory bowel disease. Am J Gastroenterol. 2021;116:1746–51. DOI: 1314309/ajg0000000000001342Botwin G.J., Li D., Figueiredo J., Cheng S., Braun J., McGovern D.P.B., et al. Adverse events after SARSCoV-2 mRNA vaccination among patients with inflammatory bowel disease. Am J Gastroenterol. 2021;116:1746–51. DOI: 1314309/ajg0000000000001342

The authors declare that there are no conflicts of interest present.